ahlam1399
06-29-2016, 06:29 PM
Tesaro?s ovarian cancer drug shows benefit in late-stage trial
(Reuters) - Tesaro Inc said its ovarian cancer drug met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares up 84 percent in premarket trading.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=aaswAReOHHI:URYJGyCVU48:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=aaswAReOHHI:URYJGyCVU48:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=aaswAReOHHI:URYJGyCVU48:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=aaswAReOHHI:URYJGyCVU48:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=aaswAReOHHI:URYJGyCVU48:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/aaswAReOHHI
(Reuters) - Tesaro Inc said its ovarian cancer drug met the main goal of prolonging survival in patients, without the disease worsening, in a late-stage trial, sending its shares up 84 percent in premarket trading.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=aaswAReOHHI:URYJGyCVU48:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=aaswAReOHHI:URYJGyCVU48:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=aaswAReOHHI:URYJGyCVU48:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=aaswAReOHHI:URYJGyCVU48:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=aaswAReOHHI:URYJGyCVU48:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/aaswAReOHHI